Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: A single-center observational study

Miyoko Naganuma, Tsuyoshi Shiga, Kumi Sato, Kagari Murasaki, Masayuki Hashiguchi, Mayumi Mochizuki, Nobuhisa Hagiwara

研究成果: Article

23 引用 (Scopus)

抄録

Background: Although a lower target prothrombin time-international normalized ratio (PT-INR) with warfarin therapy is recommended in Japan for atrial fibrillation (AF) patients ≥ 70 years of age, few studies have provided supporting data. The current study aimed to evaluate the clinical outcome in elderly Japanese patients with non-valvular AF who were taking warfarin. Methods: We conducted a cohort study of 845 consecutive non-valvular AF patients ≥ 70 years of age who were taking warfarin (median age, 74 years; 30.5% women) with a median follow-up period of 27 months (4-69 months). Of these patients, 29.7% had a history of stoke/transient ischemic attack (TIA), and 73.1% of the patients had a CHADS 2 score ≥ 2. The occurrence of thromboembolic events, including ischemic stroke, TIA and other systemic embolisms, and major bleeding events were validated through a review of medical records. Results: The incidence of thromboembolic and major bleeding events were 3.8 and 2.1% per year, respectively. A higher incidence of both events was observed in patients with a CHADS 2 score ≥ 3. The multivariate analysis showed that prior stroke/TIA (odds ratio 1.7, 95% CI 1.0-2.7) and diabetes (odds ratio 1.7, 95% CI 1.0-2.8) were independent risks of thromoembolic events. A HAS-BLED score ≥ 3 represented a risk for major bleeding (hazard ratio 2.8, 95% CI 1.7-4.6). A PT-INR of 1.5-2.5 indicated a low incidence of thromboembolic and major bleeding events in patients with a CHADS 2 score ≥ 2. Conclusions: Our results demonstrate that a target PT-INR of 2.0 and a range of 1.5-2.5 may be safe for elderly Japanese patients with non-valvular AF.

元の言語English
ページ(範囲)21-26
ページ数6
ジャーナルThrombosis Research
130
発行部数1
DOI
出版物ステータスPublished - 2012 7

Fingerprint

Warfarin
Atrial Fibrillation
Observational Studies
International Normalized Ratio
Prothrombin Time
Transient Ischemic Attack
Hemorrhage
Incidence
Stroke
Odds Ratio
Embolism
Medical Records
Japan
Cohort Studies
Multivariate Analysis

ASJC Scopus subject areas

  • Hematology

これを引用

Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin : A single-center observational study. / Naganuma, Miyoko; Shiga, Tsuyoshi; Sato, Kumi; Murasaki, Kagari; Hashiguchi, Masayuki; Mochizuki, Mayumi; Hagiwara, Nobuhisa.

:: Thrombosis Research, 巻 130, 番号 1, 07.2012, p. 21-26.

研究成果: Article

Naganuma, Miyoko ; Shiga, Tsuyoshi ; Sato, Kumi ; Murasaki, Kagari ; Hashiguchi, Masayuki ; Mochizuki, Mayumi ; Hagiwara, Nobuhisa. / Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin : A single-center observational study. :: Thrombosis Research. 2012 ; 巻 130, 番号 1. pp. 21-26.
@article{3b4986bcba8841aaa70709e5f5eda852,
title = "Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: A single-center observational study",
abstract = "Background: Although a lower target prothrombin time-international normalized ratio (PT-INR) with warfarin therapy is recommended in Japan for atrial fibrillation (AF) patients ≥ 70 years of age, few studies have provided supporting data. The current study aimed to evaluate the clinical outcome in elderly Japanese patients with non-valvular AF who were taking warfarin. Methods: We conducted a cohort study of 845 consecutive non-valvular AF patients ≥ 70 years of age who were taking warfarin (median age, 74 years; 30.5{\%} women) with a median follow-up period of 27 months (4-69 months). Of these patients, 29.7{\%} had a history of stoke/transient ischemic attack (TIA), and 73.1{\%} of the patients had a CHADS 2 score ≥ 2. The occurrence of thromboembolic events, including ischemic stroke, TIA and other systemic embolisms, and major bleeding events were validated through a review of medical records. Results: The incidence of thromboembolic and major bleeding events were 3.8 and 2.1{\%} per year, respectively. A higher incidence of both events was observed in patients with a CHADS 2 score ≥ 3. The multivariate analysis showed that prior stroke/TIA (odds ratio 1.7, 95{\%} CI 1.0-2.7) and diabetes (odds ratio 1.7, 95{\%} CI 1.0-2.8) were independent risks of thromoembolic events. A HAS-BLED score ≥ 3 represented a risk for major bleeding (hazard ratio 2.8, 95{\%} CI 1.7-4.6). A PT-INR of 1.5-2.5 indicated a low incidence of thromboembolic and major bleeding events in patients with a CHADS 2 score ≥ 2. Conclusions: Our results demonstrate that a target PT-INR of 2.0 and a range of 1.5-2.5 may be safe for elderly Japanese patients with non-valvular AF.",
keywords = "atrial fibrillation, bleeding, elderly, Japanese, stroke, warfarin",
author = "Miyoko Naganuma and Tsuyoshi Shiga and Kumi Sato and Kagari Murasaki and Masayuki Hashiguchi and Mayumi Mochizuki and Nobuhisa Hagiwara",
year = "2012",
month = "7",
doi = "10.1016/j.thromres.2011.11.005",
language = "English",
volume = "130",
pages = "21--26",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin

T2 - A single-center observational study

AU - Naganuma, Miyoko

AU - Shiga, Tsuyoshi

AU - Sato, Kumi

AU - Murasaki, Kagari

AU - Hashiguchi, Masayuki

AU - Mochizuki, Mayumi

AU - Hagiwara, Nobuhisa

PY - 2012/7

Y1 - 2012/7

N2 - Background: Although a lower target prothrombin time-international normalized ratio (PT-INR) with warfarin therapy is recommended in Japan for atrial fibrillation (AF) patients ≥ 70 years of age, few studies have provided supporting data. The current study aimed to evaluate the clinical outcome in elderly Japanese patients with non-valvular AF who were taking warfarin. Methods: We conducted a cohort study of 845 consecutive non-valvular AF patients ≥ 70 years of age who were taking warfarin (median age, 74 years; 30.5% women) with a median follow-up period of 27 months (4-69 months). Of these patients, 29.7% had a history of stoke/transient ischemic attack (TIA), and 73.1% of the patients had a CHADS 2 score ≥ 2. The occurrence of thromboembolic events, including ischemic stroke, TIA and other systemic embolisms, and major bleeding events were validated through a review of medical records. Results: The incidence of thromboembolic and major bleeding events were 3.8 and 2.1% per year, respectively. A higher incidence of both events was observed in patients with a CHADS 2 score ≥ 3. The multivariate analysis showed that prior stroke/TIA (odds ratio 1.7, 95% CI 1.0-2.7) and diabetes (odds ratio 1.7, 95% CI 1.0-2.8) were independent risks of thromoembolic events. A HAS-BLED score ≥ 3 represented a risk for major bleeding (hazard ratio 2.8, 95% CI 1.7-4.6). A PT-INR of 1.5-2.5 indicated a low incidence of thromboembolic and major bleeding events in patients with a CHADS 2 score ≥ 2. Conclusions: Our results demonstrate that a target PT-INR of 2.0 and a range of 1.5-2.5 may be safe for elderly Japanese patients with non-valvular AF.

AB - Background: Although a lower target prothrombin time-international normalized ratio (PT-INR) with warfarin therapy is recommended in Japan for atrial fibrillation (AF) patients ≥ 70 years of age, few studies have provided supporting data. The current study aimed to evaluate the clinical outcome in elderly Japanese patients with non-valvular AF who were taking warfarin. Methods: We conducted a cohort study of 845 consecutive non-valvular AF patients ≥ 70 years of age who were taking warfarin (median age, 74 years; 30.5% women) with a median follow-up period of 27 months (4-69 months). Of these patients, 29.7% had a history of stoke/transient ischemic attack (TIA), and 73.1% of the patients had a CHADS 2 score ≥ 2. The occurrence of thromboembolic events, including ischemic stroke, TIA and other systemic embolisms, and major bleeding events were validated through a review of medical records. Results: The incidence of thromboembolic and major bleeding events were 3.8 and 2.1% per year, respectively. A higher incidence of both events was observed in patients with a CHADS 2 score ≥ 3. The multivariate analysis showed that prior stroke/TIA (odds ratio 1.7, 95% CI 1.0-2.7) and diabetes (odds ratio 1.7, 95% CI 1.0-2.8) were independent risks of thromoembolic events. A HAS-BLED score ≥ 3 represented a risk for major bleeding (hazard ratio 2.8, 95% CI 1.7-4.6). A PT-INR of 1.5-2.5 indicated a low incidence of thromboembolic and major bleeding events in patients with a CHADS 2 score ≥ 2. Conclusions: Our results demonstrate that a target PT-INR of 2.0 and a range of 1.5-2.5 may be safe for elderly Japanese patients with non-valvular AF.

KW - atrial fibrillation

KW - bleeding

KW - elderly

KW - Japanese

KW - stroke

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=84861831358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861831358&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2011.11.005

DO - 10.1016/j.thromres.2011.11.005

M3 - Article

C2 - 22137743

AN - SCOPUS:84861831358

VL - 130

SP - 21

EP - 26

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 1

ER -